Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

“While ART improves the morbidity and mortality associated with HIV, it does not improve the immune system’s ability to control HIV replication, and it is also associated with significant side effects for patients,” said Principal Investigator Jean-Pierre Routy, M.D., from McGill University Health Centre in Montreal. “A new treatment strategy is needed that could potentially limit or delay exposure to ART and its accompanying side effects, and I believe that an immunotherapeutic approach may be able to achieve this, through producing or enhancing the anti-HIV immune responses needed to control viral replication.”

Charles Nicolette, Ph.D., Chief Scientific Officer and Vice President of Research and Development of Argos Therapeutics, added, “We are excited about the Arcelis immunotherapy platform because it is so well suited to the pathology of HIV infection; it overcomes the viral variability and the immune suppressive mechanisms that allow the virus to persist chronically and, remarkably, this is achieved without activation of CD4+ T cells, which are known to serve as factories for viral replication. This current study confirms previous proof-of-concept studies that have shown that our approach is able to induce a diverse immune response to HIV in patients.”

AGS-004 is produced from autologous, monocyte-derived dendritic cells that are electroporated with RNA encoding for CD40L and for HIV antigens Gag, Nef, Rev, and Vpr, derived from each patient’s pre-ART plasma. Data from this study show that four patients demonstrated increases in T cell proliferation specific to the four HIV antigens used in AGS-004, which met the criteria for a full response; three additional subjects demonstrated increases that represented partial responses to AGS-004 therapy. Importantly, HIV viral load was undetectable at baseline and throughout the duration of the study for all subjects.

Reported adverse events were all mild in nature, with no evidence of autoimmunity, and no significant changes in absolute CD4+ and CD8+ cell counts were observed. No subjects discontinued the study due to any adverse event. The study also demonstrated the manufacturing feasibility of AGS-004, which was produced according to current Good Manufacturing Procedures, with AGS-004 being produced within a mean of 6 weeks and yielding 4-12 doses per patient.

“This study demonstrates both the clinical and commercial potential of AGS-004 for HIV therapy,” said Jeff Abbey, President and CEO of Argos. “In addition to the promising immune response data observed, we have also received important data detailing a potentially favorable safety profile, as well as validation for our proprietary immunotherapy manufacturing process. Based on the strong results we have observed so far, we are near completion of a Phase 2a trial of this candidate in HIV, and will initiate a Phase 2b double blind placebo controlled study this year.”